Oxsynia Lp

Active Ingredient:: Oxycodone Hydrochloride, Naloxone Hydrochloride Dihydrate
Origin:: EU

Oxsynia Lp (Oxycodone Hydrochloride, Naloxone Hydrochloride Dihydrate)

International sale not permitted. Listed for the domestic market and B2B only.

Oxycodone Hydrochloride, the active ingredient in Oxsynia Lp, is an opioid analgesic presented as a solid oral dosage form for oral use. It treats moderate to severe pain in adult patients when other analgesics are insufficient. Naloxone Hydrochloride Dihydrate, the secondary ingredient, is included to mitigate opioid‑induced constipation and abuse potential.

GNH India supplies Oxsynia Lp as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Mundipharma Sas

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Oxycodone/Naloxone combination therapy is indicated for pain management within the opioid pathway, particularly for conditions requiring strong analgesia.

Chronic cancer pain: provides sustained relief while reducing opioid‑related side effects.
Severe postoperative pain: delivers potent analgesia after major surgery.
Chronic non‑cancer pain: offers long‑term control for patients with refractory pain where other treatments have failed.

How It Works

The formulation combines oxycodone, a μ‑opioid receptor agonist that mimics endogenous opioids to inhibit pain signaling in the central nervous system, with naloxone, a peripheral μ‑opioid antagonist that remains largely inactive when taken orally but blocks opioid receptors in the gastrointestinal tract, thereby reducing constipation and limiting abuse potential.

Side Effects

Adverse reactions may vary in frequency and severity.

Common Side Effects

Nausea: mild to moderate upset stomach.
Constipation: reduced bowel motility.
Dizziness: transient light‑headedness.
Somnolence: increased sleepiness.
Dry mouth: reduced salivation.
Pruritus: mild skin itching.

Serious or Rare Side Effects

Respiratory depression: slowed breathing requiring medical attention.
Severe hypotension: marked drop in blood pressure.
Hepatic impairment: liver function abnormalities.
Seizures: rare convulsive episodes.
Allergic reactions: rash, swelling, or anaphylaxis.
Dependence or withdrawal: signs of opioid use disorder.

Precautions & Warnings

When prescribing Oxsynia Lp, clinicians should evaluate patient history and monitor for specific risks.

Assess renal and hepatic function: adjust therapy if impairment is present.
Evaluate for respiratory disorders: avoid in severe COPD or sleep apnea.
Review concomitant CNS depressants: increased sedation risk.
Monitor for signs of abuse or dependence: educate patients on safe use.
Pregnancy and lactation: use only if benefits outweigh risks.
Store at ambient temperature: keep below 25°C in original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Oxycodone/Naloxone may interact with several medication classes, requiring clinical vigilance.

Major Interactions (Avoid)

Benzodiazepines: additive central nervous system depression.
CNS depressants: heightened risk of respiratory depression.
MAO inhibitors: potential for severe hypertension or serotonin syndrome.

Moderate Interactions (Monitor Closely)

CYP3A4 inhibitors (e.g., ketoconazole): increased oxycodone plasma levels.
CYP3A4 inducers (e.g., rifampicin): reduced analgesic effect.
Anticholinergics: may exacerbate constipation despite naloxone component.

Frequently Asked Questions

Oxsynia Lp is a fixed‑dose combination of oxycodone and naloxone indicated for the management of moderate to severe pain, including chronic cancer pain, postoperative pain and refractory chronic non‑cancer pain when other analgesics are insufficient.

Oxycodone acts as a μ‑opioid receptor agonist in the central nervous system, mimicking natural endorphins to block pain transmission pathways, while the naloxone component remains largely inactive systemically but antagonises peripheral opioid receptors to reduce constipation and limit abuse potential.

The prescribed dose of Oxsynia Lp is individualized by the treating physician based on pain severity, prior opioid exposure, renal and hepatic function, and patient tolerance. Dosage adjustments follow clinical guidelines and local regulatory requirements.

Oxsynia Lp should be used during pregnancy or lactation only if the expected benefit justifies potential risks to the fetus or infant. Opioids can affect fetal development and may be excreted in breast milk, so clinicians must weigh benefits against possible adverse outcomes.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with single‑agent opioids, Oxsynia Lp combines oxycodone with naloxone, which helps reduce opioid‑induced constipation and lowers abuse potential. This dual action can improve tolerability while delivering comparable analgesic potency to other strong opioids such as morphine or fentanyl.

Store Oxsynia Lp at ambient temperature, below 25 °C, in its original packaging. Protect the tablets from moisture, excessive heat and direct sunlight to maintain stability and potency.

Oxsynia Lp is taken orally, usually with water, and may be administered with or without food. Patients should follow the prescribing clinician’s instructions regarding timing and any necessary dose adjustments.

The most serious risks include respiratory depression, severe hypotension, hepatic impairment, seizures, allergic reactions such as anaphylaxis, and the potential for opioid dependence or withdrawal if the medication is discontinued abruptly.

Oxsynia Lp is contraindicated in patients with known hypersensitivity to oxycodone, naloxone or any formulation components, in those with severe respiratory depression, acute or severe asthma, and in individuals taking MAO inhibitors within 14 days.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 10 Oct 2026

Disclaimer

International sale not permitted. Listed for the domestic market and B2B only.

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.